Concepts (163)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Biological Specimen Banks | 4 | 2022 | 51 | 1.100 |
Why?
|
| Retinoblastoma | 3 | 2012 | 110 | 0.720 |
Why?
|
| Biomedical Research | 3 | 2020 | 519 | 0.620 |
Why?
|
| Oncolytic Viruses | 3 | 2013 | 72 | 0.460 |
Why?
|
| Retinal Neoplasms | 2 | 2012 | 100 | 0.450 |
Why?
|
| Picornaviridae | 2 | 2013 | 20 | 0.400 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2012 | 87 | 0.390 |
Why?
|
| Antigens, CD | 1 | 2012 | 421 | 0.340 |
Why?
|
| Glycoproteins | 1 | 2012 | 371 | 0.330 |
Why?
|
| Retina | 1 | 2012 | 454 | 0.310 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 619 | 0.310 |
Why?
|
| Peptides | 1 | 2012 | 793 | 0.310 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2007 | 197 | 0.240 |
Why?
|
| Genetic Therapy | 1 | 2007 | 682 | 0.210 |
Why?
|
| Public Opinion | 1 | 2022 | 56 | 0.200 |
Why?
|
| Genome-Wide Association Study | 2 | 2020 | 1653 | 0.180 |
Why?
|
| Receptor, Notch4 | 1 | 2020 | 4 | 0.180 |
Why?
|
| Oncolytic Virotherapy | 2 | 2013 | 84 | 0.180 |
Why?
|
| Heart Septal Defects | 1 | 2020 | 40 | 0.180 |
Why?
|
| Research Personnel | 1 | 2020 | 117 | 0.160 |
Why?
|
| Repressor Proteins | 2 | 2016 | 821 | 0.160 |
Why?
|
| Cytoskeletal Proteins | 1 | 2020 | 268 | 0.160 |
Why?
|
| Neoplasm Transplantation | 2 | 2011 | 374 | 0.160 |
Why?
|
| Antigens, Neoplasm | 1 | 2020 | 382 | 0.150 |
Why?
|
| Down Syndrome | 1 | 2020 | 195 | 0.150 |
Why?
|
| Hypoplastic Left Heart Syndrome | 2 | 2022 | 252 | 0.150 |
Why?
|
| Heart Defects, Congenital | 2 | 2022 | 1813 | 0.140 |
Why?
|
| Brain Neoplasms | 3 | 2013 | 1241 | 0.140 |
Why?
|
| Proteomics | 1 | 2020 | 488 | 0.140 |
Why?
|
| Cell Cycle Proteins | 1 | 2020 | 645 | 0.130 |
Why?
|
| RNA Splicing Factors | 1 | 2016 | 50 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2016 | 32 | 0.130 |
Why?
|
| Quality Control | 1 | 2016 | 119 | 0.130 |
Why?
|
| Codon, Nonsense | 1 | 2016 | 132 | 0.130 |
Why?
|
| Specimen Handling | 1 | 2016 | 141 | 0.120 |
Why?
|
| Myocytes, Cardiac | 2 | 2022 | 622 | 0.120 |
Why?
|
| Alternative Splicing | 1 | 2016 | 350 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 2 | 2012 | 1064 | 0.110 |
Why?
|
| Genomics | 1 | 2020 | 1486 | 0.100 |
Why?
|
| Phenotype | 1 | 2022 | 4252 | 0.100 |
Why?
|
| PAX6 Transcription Factor | 1 | 2012 | 37 | 0.100 |
Why?
|
| AC133 Antigen | 1 | 2012 | 35 | 0.100 |
Why?
|
| Paired Box Transcription Factors | 1 | 2012 | 75 | 0.100 |
Why?
|
| RNA, Messenger | 2 | 2016 | 2823 | 0.100 |
Why?
|
| Disease Models, Animal | 3 | 2013 | 4344 | 0.090 |
Why?
|
| Immunophenotyping | 1 | 2012 | 329 | 0.090 |
Why?
|
| Eye Proteins | 1 | 2012 | 219 | 0.090 |
Why?
|
| Blood-Brain Barrier | 1 | 2010 | 141 | 0.080 |
Why?
|
| Flow Cytometry | 1 | 2012 | 803 | 0.080 |
Why?
|
| Humans | 18 | 2022 | 124399 | 0.080 |
Why?
|
| Stem Cells | 1 | 2014 | 702 | 0.080 |
Why?
|
| Mice | 6 | 2013 | 17728 | 0.080 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 546 | 0.080 |
Why?
|
| Glioma | 1 | 2013 | 500 | 0.080 |
Why?
|
| Neoplastic Stem Cells | 1 | 2010 | 300 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2012 | 719 | 0.070 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2007 | 77 | 0.070 |
Why?
|
| Medulloblastoma | 1 | 2010 | 340 | 0.070 |
Why?
|
| Hyaluronan Receptors | 1 | 2006 | 66 | 0.070 |
Why?
|
| Mice, Transgenic | 1 | 2012 | 2414 | 0.070 |
Why?
|
| Cystadenoma, Serous | 1 | 2005 | 5 | 0.060 |
Why?
|
| Hyaluronic Acid | 1 | 2006 | 95 | 0.060 |
Why?
|
| Azetidines | 1 | 2006 | 55 | 0.060 |
Why?
|
| Transduction, Genetic | 1 | 2006 | 289 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 1 | 2007 | 606 | 0.060 |
Why?
|
| Child | 4 | 2020 | 24486 | 0.060 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2005 | 58 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 3125 | 0.060 |
Why?
|
| Neoplasm Metastasis | 1 | 2007 | 662 | 0.060 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2006 | 345 | 0.060 |
Why?
|
| Animals | 6 | 2013 | 34128 | 0.060 |
Why?
|
| Phyllodes Tumor | 1 | 2004 | 11 | 0.060 |
Why?
|
| Vaginal Neoplasms | 1 | 2004 | 14 | 0.060 |
Why?
|
| Myxoma | 1 | 2004 | 29 | 0.060 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2004 | 62 | 0.060 |
Why?
|
| Leiomyosarcoma | 1 | 2004 | 29 | 0.060 |
Why?
|
| Adenoviridae | 1 | 2006 | 603 | 0.060 |
Why?
|
| Trimethylsilyl Compounds | 1 | 2003 | 2 | 0.050 |
Why?
|
| Peritoneal Neoplasms | 1 | 2004 | 28 | 0.050 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2003 | 77 | 0.050 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2003 | 43 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2005 | 350 | 0.050 |
Why?
|
| Uterine Neoplasms | 1 | 2004 | 116 | 0.050 |
Why?
|
| Image Cytometry | 1 | 2022 | 14 | 0.050 |
Why?
|
| Bone Morphogenetic Protein Receptors | 1 | 2022 | 10 | 0.050 |
Why?
|
| Steroids | 1 | 2003 | 203 | 0.050 |
Why?
|
| Injections, Intravenous | 2 | 2013 | 254 | 0.050 |
Why?
|
| Ovarian Neoplasms | 1 | 2005 | 410 | 0.050 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2022 | 152 | 0.040 |
Why?
|
| Mice, SCID | 2 | 2013 | 571 | 0.040 |
Why?
|
| Tetralogy of Fallot | 1 | 2022 | 163 | 0.040 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2022 | 213 | 0.040 |
Why?
|
| Monocytes | 1 | 2022 | 352 | 0.040 |
Why?
|
| Forkhead Transcription Factors | 1 | 2022 | 366 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2022 | 273 | 0.040 |
Why?
|
| Canada | 1 | 2020 | 295 | 0.040 |
Why?
|
| Focus Groups | 1 | 2020 | 202 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2020 | 4730 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2013 | 887 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2020 | 280 | 0.040 |
Why?
|
| Vulnerable Populations | 1 | 2020 | 140 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2005 | 1000 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 749 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2004 | 1125 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2022 | 891 | 0.040 |
Why?
|
| Insulin Resistance | 1 | 2022 | 644 | 0.030 |
Why?
|
| Treatment Outcome | 3 | 2007 | 12285 | 0.030 |
Why?
|
| Disease Progression | 1 | 2022 | 2038 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2020 | 8181 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2020 | 782 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2016 | 426 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2014 | 232 | 0.030 |
Why?
|
| Cell Communication | 1 | 2014 | 167 | 0.030 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2013 | 27 | 0.030 |
Why?
|
| Amniotic Fluid | 1 | 2014 | 153 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2016 | 1082 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2014 | 764 | 0.030 |
Why?
|
| Troponin T | 1 | 2014 | 245 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2004 | 2503 | 0.020 |
Why?
|
| Heart Ventricles | 1 | 2016 | 770 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 254 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2006 | 2038 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 261 | 0.020 |
Why?
|
| Female | 6 | 2020 | 66372 | 0.020 |
Why?
|
| Genotype | 1 | 2016 | 2546 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2022 | 4532 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2013 | 1479 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 1110 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 1289 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 2604 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2014 | 1932 | 0.020 |
Why?
|
| Survival Rate | 1 | 2010 | 2021 | 0.020 |
Why?
|
| Ezetimibe | 1 | 2006 | 95 | 0.020 |
Why?
|
| Pulsatile Flow | 1 | 2005 | 126 | 0.020 |
Why?
|
| Infant | 1 | 2020 | 12464 | 0.020 |
Why?
|
| Vascular Resistance | 1 | 2005 | 186 | 0.020 |
Why?
|
| United States | 1 | 2020 | 10757 | 0.010 |
Why?
|
| Mastectomy, Simple | 1 | 2004 | 2 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2005 | 586 | 0.010 |
Why?
|
| Omentum | 1 | 2004 | 47 | 0.010 |
Why?
|
| Apoptosis | 1 | 2010 | 1791 | 0.010 |
Why?
|
| Hydroxylation | 1 | 2003 | 45 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 3341 | 0.010 |
Why?
|
| Cytochrome P-450 CYP1B1 | 1 | 2003 | 29 | 0.010 |
Why?
|
| Calibration | 1 | 2003 | 88 | 0.010 |
Why?
|
| Catalysis | 1 | 2003 | 126 | 0.010 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2004 | 69 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2011 | 2055 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2006 | 939 | 0.010 |
Why?
|
| Postpartum Period | 1 | 2004 | 216 | 0.010 |
Why?
|
| Male | 2 | 2020 | 60951 | 0.010 |
Why?
|
| Cell Line | 1 | 2006 | 2769 | 0.010 |
Why?
|
| Pregnancy Outcome | 1 | 2004 | 609 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2006 | 813 | 0.010 |
Why?
|
| Adult | 3 | 2005 | 29422 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 1394 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2004 | 948 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 2870 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2006 | 4422 | 0.010 |
Why?
|
| Middle Aged | 2 | 2005 | 26440 | 0.010 |
Why?
|
| Mutation | 1 | 2006 | 5806 | 0.010 |
Why?
|
| Pregnancy | 1 | 2004 | 7249 | 0.010 |
Why?
|
| Adolescent | 1 | 2005 | 19327 | 0.000 |
Why?
|